Galderma’s Nemluvio gains FDA nod for moderate-to-severe atopic dermatitis
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of Nemluvio (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients ... Read More
Galderma’s breakthrough drug Nemluvio gains rapid FDA approval for severe itch condition
Galderma has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving Nemluvio (nemolizumab) for the treatment of prurigo nodularis in adults. ... Read More